- You can view the full Novo Nordisk A/S Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
Novo Nordisk (NVO) stock rating was increased to 'buy' at Deutsche Bank.
Novo Nordisk (NVO) CEO Lars Rebien Sorensen will leave the company as it faces continued pressure in the insulin market.